Recombinant human erythropoietin versus placebo or no treatment for the anaemia of chronic kidney disease in people not requiring dialysis-Reference-Cited by-同舟云学术

Recombinant human erythropoietin versus placebo or no treatment for the anaemia of chronic kidney disease in people not requiring dialysis

Published:2016-01-20 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Cody June D¹,Hodson Elisabeth M²

Affiliation:

1. University of Aberdeen; Cochrane Incontinence Review Group; 2nd Floor, Health Sciences Building Health Sciences Building Foresterhill Aberdeen UK AB25 2ZD

2. The Children's Hospital at Westmead; Cochrane Kidney and Transplant, Centre for Kidney Research; Locked Bag 4001 Westmead NSW Australia 2145

Publisher

Wiley

Subject

Pharmacology (medical)

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/14651858.CD003266.pub3/fullpdf

Reference108 articles.

1. Renal function during erythropoietin therapy for anemia in predialysis chronic renal failure patients;Abraham;American Journal of Nephrology,1990

2. Recombinant-human erythropoietin (EPO) in chronic renal failure (CRF): no adverse effect on renal hemodynamics or progression of disease [abstract];Opsahl;Kidney International,1989

3. Akizawa T Koshikawa S Effect of rHuEPO on progression of renal disease [abstract] 12th International Congress of Nephrology; 1993 June 13-18; Jerusalem, Israel 1993 300

4. Erythropoietin delays the onset of uremia in anemic azotemic diabetic predialysis patients [abstract];Brown;Journal of the American Society of Nephrology,1995

5. Effect of erythropoietin treatment on physical exercise capacity and on renal function in predialytic uremic patients;Clyne;Nephron,1992

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Erythropoietin N-glycosylation of Therapeutic Formulations Quantified and Characterized: An Interlab Comparability Study of High-Throughput Methods;Biomolecules;2024-01-18

2. Anemia and Hypoxia Impact on Chronic Kidney Disease Onset and Progression: Review and Updates;Cureus;2023-10-09

3. The anaemia treatment journey of CKD patients: from epoetins to hypoxia-inducible factor-prolyl hydroxylase inhibitors;Clinical Kidney Journal;2023-08-17

4. Hemoglobin modulation affects physiology and patient reported outcomes in anemic and non-anemic subjects: An umbrella review;Frontiers in Physiology;2023-02-15

5. Clinical Observation of Roxadustat Capsule on Iron Metabolism of Anemia in Patients with Initial Peritoneal Dialysis;Advances in Clinical Medicine;2023